Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6314-6323

  Armenian, Saro H ^a   Gelehrter, Sarah K ^f   Vase, Tabitha ^a   Venkatramani, Rajkumar ^c,e   Lier, Wendy ^a   Wilson, Karla D ^a   Herrera, Claudia ^a   Reichman, Leah ^c   Menteer, John David ^d,e   Mascarenhas, Leo ^c,e   Freyer, David R ^c,e   Venkataraman, Kalyanasundaram ^b   Bhatia, Smita ^a  

^a Division of Outcomes Research   (United States)

^b Department of Cardiology City of Hope ^*  (United States)

^c Divisionof Hematology Oncology Blood and Marrow Transplantation   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; PROTEIN ST 2; TROPONIN T; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVOR; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CHILD; CHILDHOOD CANCER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; ECHOCARDIOGRAPHY; FEMALE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PERFORMANCE; HEART VENTRICLE REMODELING; HEART VENTRICLE WALL; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; BLOOD; CASE CONTROL STUDY; COMPLICATION; HEART DISEASES; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; NEOPLASMS; PATHOPHYSIOLOGY; RISK FACTOR; SURVIVOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOMARKERS; CASE-CONTROL STUDIES; CHILD; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SURVIVORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 84919658389     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3490     Document Type: Article

References (39)

1. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013;128:1927-95.
2. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-36.
3. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
4. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005;44:600-6.
5. van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a longterm follow-up study. Eur J Cancer 2006;42:3191-8.
6. Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013;112: 1980-4.
7. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342: 1077-84.
8. Armenian SH, Sun CL, Francisco L, Steinberger J, Kurian S, Wong FL, et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008;26:5537-43.
9. Shankar SM, Marina N, HudsonMM,Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387-96.
10. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC II, Shaikh SL, MoneSM, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002;20:4517-22.
11. Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007;25:3635-43.
12. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol 1995;26: 357-66.
13. Arnlov J, Ingelsson E, Riserus U, Andren B, Lind L. Myocardial performance index, a Doppler-derived index of global left ventricular function, predicts congestive heart failure in elderly men. Eur Heart J 2004;25:2220-5.
14. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. 3.0 ed. Arcadia, CA: Children's Oncology Group; 2008.
15. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003;42:954-70.
16. Ganame J, Claus P, Uyttebroeck A, Renard M, D'Hooge J, Bijnens B, et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr 2007;20:1351-8.
17. Aggarwal S, Pettersen MD, Gurckzynski J, L'Ecuyer T. Measuring stress velocity index using mean blood pressure: simple yet accurate? Pediatr Cardiol 2008;29:108-12.
18. Ruschhaupt DG, Sodt PC, Hutcheon NA, Arcilla RA. Estimation of circumferential fiber shortening velocity by echocardiography. J Am Coll Cardiol 1983;2:77-84.
19. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, et al. Additive benefi cial effects of beta-blockers to angiotensinconverting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997;29:229-36.
20. Pettersen MD, Du W, Skeens ME,Humes RA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 2008;21:922-34.
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantifi cation Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
22. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154:596-602.
23. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855-7.
24. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003;97:1991-8.
25. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004;91:37-44.
26. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubi-cin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010;11:950-61.
27. Paulides M, Kremers A, Stohr W, Bielack S, Jurgens H, Treuner J, et al. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer 2006;46: 489-95.
28. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002;13: 819-29.
29. Colan SD, Shirali G, Margossian R, Gallagher D, Altmann K, Canter C, et al. The ventricular volume variability study of the Pediatric Heart Network: study design and impact of beat averaging and variable type on the reproducibility of echocardiographic measurements in children with chronic dilated cardiomyopathy. J Am Soc Echocardiogr 2012; 25:842-54.e6.
30. Arnlov J, Lind L, Andren B, Riserus U, Berglund L, Lithell H. A Dopplerderived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men. Am Heart J 2005;149:902-7.
31. Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, et al. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation 2009;119:2679-85.
32. Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 2001;87:1120-2.
33. Karakurt C, Kocak G, Ozgen U. Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography 2008;25:880-7.
34. Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007;49:812-6.
35. Germanakis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Patrianakos A, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 2006;108:212-5.
36. Pinarli FG, Oguz A, Tunaoglu FS, Karadeniz C, Gokcora N, Elbeg S. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005;44: 370-7.
37. Sieswerda E, Postma A, van Dalen EC, van der Pal HJ, Tissing WJ, Rammeloo LA, et al. The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol 2012;23:2191-8.
38. Monsuez JJ. Detection and prevention of cardiac complications of cancer chemotherapy. Arch Cardiovasc Dis 2012;105:593-604.
39. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;30:2876-84.